Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 12/16/14  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Peter J. Goss

Wrong Dr. Peter J. Goss?

School Education Program Director

Phone: +61 *********
Email: p***@***.au
Grattan Institute
8 Malvina Place
Carlton , Victoria 3053
Australia

Company Description: Grattan Institute is truly non-aligned and well-resourced. The independence of Grattan Institute allows it to tackle and publicise issues in the public interest,...   more
Background

Employment History

17 Total References
Web References
Home > About Us > People ...
grattan.edu.au, 18 Oct 2014 [cached]
Home > About Us > People > Pete Goss
...
Pete Goss
peter.goss@grattan.edu.au
Dr Pete Goss has over 10 years' experience as a strategy consultant, most recently with the Boston Consulting Group, advising Federal and State governments on service delivery innovation.
Capture the opportunity: Bio21
www.bio21.unimelb.edu.au, 30 Aug 2006 [cached]
Dr Peter Goss
Head of Bio-Innovation Division and Business Development Manager
Tel: 8344 2219
pgoss@unimelb.edu.au
People | Grattan Institute
grattan.edu.au, 18 Oct 2014 [cached]
Pete Goss
Press Enterprise, Inc
www.pressenterpriseonline.com, 25 April 2005 [cached]
U.S. and Canadian scientists, led by Harvard's Dr. Peter Goss, have begun recruiting thousands of women at high risk of breast cancer to participate in a study of what may well be just such a drug.
...
This class of drugs , which includes Astra Zeneca's Arimidex and Pfizer's Aromasin , has already been shown, as Dr. Goss puts it, to "profoundly" reduce the risk of recurrence in women who have already been diagnosed and treated for breast cancer , and to do so with fewer side effects than an earlier drug, Tamoxifen.Arimidex decreased the chance of cancer developing in the other breast by almost 80 percent.
These results offer real hope for preventing breast cancer in healthy post-menopausal women at high risk of the disease.Indeed, Goss is on record as saying he hopes that this large study will show that Aromasin cuts the rate of breast cancer by nearly 70 percent.
BREAST CANCER: NEWS TOO GOOD
www.freerepublic.com, 3 April 2005 [cached]
U.S. scientists, led by Harvard's Dr. Peter Goss, this week began recruiting women at high risk of breast cancer to participate in a study of what may well be just such a drug.
...
This class of drugs , which includes Astra Zeneca's Arimidex and Pfizer's Aromasin , has already been shown, as Dr. Goss puts it, to "profoundly" reduce the risk of recurrence in women who have already been diagnosed and treated for breast cancer , and to do so with fewer side effects than an earlier drug, Tamoxifen.
Other People with the name "Goss":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304